Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Leukemia, Myeloid, Chronic-Phase 22Leukemia 21Gastrointestinal Stromal Tumors 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasms 8Blast Crisis 7Neoplasm Metastasis 6Philadelphia Chromosome 4Myeloproliferative Disorders 4Melanoma 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Colorectal Neoplasms 2Substance Withdrawal Syndrome 1Sarcoma 1Retroperitoneal liposarcoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Peritoneal Neoplasms 1Neurofibromatoses 1

Interventions

ibrutinib 9tofacitinib 7Imatinib Mesylate 5ruxolitinib 4ofatumumab 4Rituximab 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Sirolimus 3Mycophenolic Acid 3Cyclophosphamide 3obinutuzumab 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Filgrastim 2Alemtuzumab 2ziconotide 1sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Bronchiolitis Obliterans Syndrome × nilotinib × Clear all
NCT01844765 2021-04-22

DIALOG

Novartis

Phase 2 Completed
59 enrolled 33 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00802841 2015-11-16

LASOR

Novartis

Phase 3 Completed
191 enrolled 13 charts
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01819389 2014-01-07

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Hospital Universitario Dr. Jose E. Gonzalez

Phase 3 Completed
10 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡